Value proposition

Accelerating treatments for millions of patients

Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development, as well as sharply reducing the enormous cost and time to bring effective treatments to millions of patients.

AT leverages over 20 years of international genomics research, pioneering a novel approach to guide its drug development.

The company collaborates closely with The Center for Applied Genomics (CAG) at the Children’s Hospital of Philadelphia to repurpose and develop ground-breaking new medical treatments.

AT-001, AT's Alzheimer‘s drug candidate, has the potential to become the first cure for dementia, not only treating the disease but preventing it.

AT was founded by one of the leading minds in applied genomics, Dr. Hakon Hakonarson, who launched CAG in 2006 and established it as the largest paediatric biobank and genomic database in the world.

drug discovery, genealogical database, precision-based drug development, diagnostic testing, genetic information, and therapeutic development